Objectives This is a randomized trial adopted to evaluate the safety and efficacy of
immunization with specific anti-hepatocellular carcinoma dendritic cells (DCs) in Egyptian …

Abstract Background Dendritic cells (DCs) could be used as potential cellular adjuvant for
the production of specific tumor vaccines. Objectives Our study was aimed to evaluate the …

This is a phase II clinical trial investigating the safety and efficacy of intravenous vaccination
with mature autologous dendritic cells (DCs) pulsed ex vivo with a liver tumor cell line lysate …

Hepatocellular carcinoma (HCC) is a common and rapidly progressing malignancy. Current
treatment options for advanced HCC are limited. This clinical study of dendritic cell (DC) …

Background/aims To evaluate the safety and feasibility of immunotherapy based on
autologous dendritic cells (DC) for patients with unresectable primary liver cancer (PLC) …

Dendritic cells (DCs) are increasingly used as adjuvants for vaccination strategies; however,
there has been very little development in DC vaccines for patients with hepatocellular …

Our previous phase I/IIA study showed that autologous dendritic cells (DCs) pulsed with
tumor-associated antigens are well tolerated in patients with hepatocellular carcinoma …

Background: To date, no adjuvant treatment has been shown to have a clear benefit in
patients with hepatocellular carcinoma (HCC). In this prospective phase I/IIa study, we …

Dendritic cells (DCs) are the most potent professional antigen-presenting cells, and capable
of stimulating naïve T cells and driving primary immune responses. DCs are poised to …

Purpose The aim of this study was to evaluate the clinical response of immunotherapy with
dendritic cell-cytotoxic T lymphocytes (DC-CTLs) in patients with hepatocellular carcinoma …